1. Salmonella enterica Typhimurium engineered for nontoxic systemic colonization of autochthonous tumors.
- Author
-
Augustin LB, Milbauer L, Hastings SE, Leonard AS, Saltzman DA, and Schottel JL
- Subjects
- Animals, Female, Mammary Neoplasms, Experimental therapy, Mice, Mice, Inbred BALB C, Mice, Transgenic, Salmonella typhimurium genetics, Salmonella typhimurium pathogenicity, Genetic Engineering, Mammary Neoplasms, Experimental microbiology, Salmonella typhimurium physiology
- Abstract
Much of the bacterial anticancer therapy being developed relies on the ability of bacteria to specifically colonise tumours. Initial attempts to translate promising Salmonella enterica Typhimurium ( S . Typhimurium) preclinical results to the clinical setting failed, primarily due to lack of tumour colonisation and the significant toxicities from systemically administered Gram-negative bacteria. To address the difference in results between preclinical experiments performed in mice with transplant tumours and clinical trials in human volunteers with autochthonous tumours, a genetically engineered mouse model of breast cancer (BALB-neuT) was utilised to develop a strain of virulence-attenuated S . Typhimurium capable of robust colonisation of autochthonous tumours. Several genes that code for bacterial surface molecules, responsible for signalling a toxic immune response against the bacteria, were mutated. The resulting S. Typhimurium strain, BCT2, allowed non-toxic intravenous administration of 3 × 10
6 colony forming units of bacteria in tumour-burdened mice when combined with a vascular disruption agent to induce intratumoral necrotic space and facilitate bacterial colonisation.- Published
- 2021
- Full Text
- View/download PDF